Biotechnology - Licensing, Neurological

Filter

Current filters:

LicensingNeurological

Popular Filters

1 to 25 of 43 results

Merck & Co in new accord with Bionomics for CNS research

Merck & Co in new accord with Bionomics for CNS research

24-06-2014

Australian biotech firm Bionomics has entered into a second exclusive research collaboration and license…

BionomicsBiotechnologyBNC375LicensingMerck & CoNeurologicalResearch

Inovio acquires rights to pioneering DNA research in Alzheimer's disease and MS

Inovio acquires rights to pioneering DNA research in Alzheimer's disease and MS

13-05-2014

US biotech company Inovio Pharmaceuticals has acquired worldwide rights (excluding China) for early preclinical…

BiologyBiotechnologyFudan University's Shanghai Medical CollegeInovio PharmaceuticalsLicensed technologiesLicensingMedicineNeurologicalProfessorUSA

Biotie to regain global rights to tozadenant from UCB

Biotie to regain global rights to tozadenant from UCB

26-03-2014

Finland-based Biotie Therapies says that partner Belgium-based drugmaker, following a portfolio review,…

BiotechnologyBiotie TherapiesLicensingNeurologicaltozadenantUCB

Xenon and Genentech establish new pain discovery collaboration

26-03-2014

Privately-held US biotech firm Xenon Pharmaceuticals has established a new collaboration with Swiss drug…

BiotechnologyGenentechLicensingNeurologicalResearchRocheXenon Pharmaceuticals

Eisai and Biogen Idec collaborate on Alzheimer’s disease treatments

Eisai and Biogen Idec collaborate on Alzheimer’s disease treatments

05-03-2014

US biotech firm Biogen Idec and Japanese drugmaker Eisai have entered into a collaboration to develop…

BAN2401BIIB037Biogen IdecBiotechnologyE2609EisaiLicensingNeurologicalResearch

Another milestone for GenVec in hearing and balance collaboration

13-02-2014

US biotech firm GenVec says it has achieved the third milestone in its collaboration with Swiss drug…

BiotechnologyCGF166FinancialGenVecLicensingNeurologicalNovartis

UCB and Biogen sign Asian license agreement for MS drugs

UCB and Biogen sign Asian license agreement for MS drugs

30-01-2014

Belgian drugmaker UCB and US biotech firm Biogen Idec have signed exclusive agreements granting UCB the…

AlprolixAsia-PacificBiogen IdecBiotechnologyEloctateLicensingNeurologicalPharmaceuticalTecfideraUCB

Prothena to get $30 million upfront from Roche triggered by regulatory milestone

Prothena to get $30 million upfront from Roche triggered by regulatory milestone

23-01-2014

Clinical-stage biotech firm Prothena said today that it will receive the $30 million upfront payment…

BiotechnologyFinancialLicensingNeurologicalProthenaPRX002Roche

Prothena inks deal with Roche, worth a potential $600 million

Prothena inks deal with Roche, worth a potential $600 million

12-12-2013

Biotech firm Prothena has entered into a worldwide collaboration with Swiss drug major Roche to develop…

BiotechnologyGlobalLicensingNeurologicalProthenaPRX002ResearchRoche

Proteostasis Therapeutics in neurodegenerative disease deal with Biogen Idec

Proteostasis Therapeutics in neurodegenerative disease deal with Biogen Idec

10-12-2013

US drug developer Proteostasis Therapeutics has entered into a worldwide collaboration with biotech major…

Biogen IdecBiotechnologyLicensingNeurologicalProteostasis TherapeuticsResearch

Oncodesign and UCB enter into collaboration for development of Nanocyclix in neurodegenerative diseases

13-11-2013

French drug discovery company Oncodesign has entered into a research collaboration and exclusive license…

BiotechnologyEuropeLicensingNeurologicalOncodesignUCB

Lundbeck and Otsuka partner on Biotie’s nalmefene in Japan

Lundbeck and Otsuka partner on Biotie’s nalmefene in Japan

31-10-2013

Biotie Therapies says that its partner, Lundbeck has expanded its existing alliance with Otsuka Pharmaceutical…

Asia-PacificBiotechnologyBiotie TherapiesLicensingLundbeckMarkets & MarketingnalmefeneNeurologicalSelincro

Biogen Idec in deal with Amicus for Parkinson's disease

11-09-2013

US biotech firm Amicus Therapeutics (Nasdaq: FOLD) has entered a collaboration with Biogen Idec (Nasdaq:…

Amicus TherapeuticsBiogen IdecBiotechnologyLicensingNeurologicalResearch

Biogen Idec and Isis Pharma collaborate in $100 million upfront deal

10-09-2013

US biotech firms Biogen Idec (Nasdaq: BIIB) and Isis Pharmaceuticals (Nasdaq: ISIS) have entered into…

Biogen IdecBiotechnologyIsis PharmaceuticalsLicensingNeurologicalResearch

Bionomics in $172 million pain treatment deal with US pharma giant

01-08-2013

Australian biotech firm Bionomics (ASX: BNO) has entered an agreement with US pharma giant Merck & Co…

BionomicsBiotechnologyLicensingMerck & CoNeurologicalPharmaceuticalResearch

Acetylon snags $100 million upfront cash and acquisition option

30-07-2013

Privately-held Acetylon and US biotech firm Celgene (Nasdaq: CELG) have entered into an exclusive strategic…

Acetylon PharmaceuticalsBiotechnologyCelgeneLicensingMergers & AcquisitionsNeurologicalOncology

Celgene partners with FORMA Thera on drugs targeting protein homeostasis

30-04-2013

Privately-held FORMA Therapeutics has entered into a strategic collaboration agreement with US biotech…

BiotechnologyCelgeneFORMA TherapeuticsLicensingNeurologicalOncologyResearch

GSK returns IPX066 rights to Impax; Merck & Co and Pfizer link up on diabetes drug

30-04-2013

US biotech firm Impax Laboratories (Nasdaq: IPXL) saw its shares fall 2% to $17.32 in premarket trading,…

BiotechnologyDiabetesertugliflozinGlaxoSmithKlineImpax LaboratoriesIPX066LicensingMerck & CoNeurologicalPfizerPharmaceuticalResearch

Cerecor acquires rights to NR2B receptor antagonist from Merck & Co

22-04-2013

Privately-held US neuroscience biotech firm Cerecor says that it has acquired exclusive, worldwide rights…

BiotechnologyCerecorLicensingMerck & CoMK-0657Neurological

Cerecor acquires rights to Merck & Co's COMT inhibitors

22-03-2013

US neuroscience biotech company Cerecor has acquired exclusive, worldwide rights to develop, register…

BiotechnologyCerecorLicensingMerck & CoNeurologicalPharmaceutical

Jazz Pharma and Concert ink deal on deuterium-modified sodium oxybate

27-02-2013

US drugmakers Jazz Pharmaceuticals (Nasdaq: JAZZ) and Concert Pharmaceuticals have entered into an exclusive…

BiotechnologyConcert PharmaceuticalsJazz PharmaceuticalsLicensingNeurologicalPharmaceuticalResearchsodium oxybateZyrem

Merck Serono to in-license Opexa's MS drug candidate Tcelna

06-02-2013

USA-based Opexa Therapeutics (Nasdaq: OPXA) has entered into an agreement with Merck Serono, a division…

BiotechnologyLicensingMerck KGaAMerck SeronoNeurologicalOpexa TherapeuticsPharmaceuticalTcelna

Teva pulls out of CureTech deal; AC Immune drops CI-91

01-02-2013

Israel-based Teva Pharmaceutical Industries (NYSE: TEVA) says that it has terminated its collaboration…

AC ImmuneBiotechnologyCT-011CureTechLicensingNeurologicalOncologyPharmaceuticalResearchTeva Pharmaceutical Industries

Repligen in $70 million deal with Pfizer for SMA program

04-01-2013

USA-based Repligen (Nasdaq: RGEN) saw its share jump 5.6% to $6.63, after the company revealed it has…

BiotechnologyLicensingNeurologicalPfizerPharmaceuticalRare diseasesRepligenRG3039

1 to 25 of 43 results

Back to top